LSE:HLN 15 February 2026 - 14 May 2026

Haleon (LON:HLN) jumps in London trade, volume high as Sensodyne gains offset OTC weakness
·

Haleon (LON:HLN) jumps in London trade, volume high as Sensodyne gains offset OTC weakness

Haleon PLC ended the session quoted at 367.00p/367.10p, gaining 1.92% from Monday. FTSE 100 added 0.13%, according to Hargreaves Lansdown. Monday, Haleon dropped 1.59% to £3.59 as it trailed a 0.26% slide in the blue-chip index. The move wasn’t just about price. On Monday, the stock dropped with volume at 12.6 million shares, well below the 50-day average of 25.4 million shown in Monday’s data. Volume jumped to 37.49 million shares during Tuesday’s rebound. The bounce had more trading behind it than the decline.
July 7, 2026
Haleon’s New UEFA Medical Deal Puts Voltaren in Football Spotlight—But Shares Lag
····

Haleon’s New UEFA Medical Deal Puts Voltaren in Football Spotlight—But Shares Lag

Haleon PLC is now the first Health Partner for UEFA Medical, landing the maker of Sensodyne and Voltaren a new foothold in football medicine. The move comes as Haleon looks to spotlight its over-the-counter pain brands in a consumer health sector that's turning more challenging. The company and UEFA have signed a multi-year deal aimed at advancing evidence-based pain management—think topical treatments, digital training modules, and webinars designed for medical staff. Topical NSAIDs, a class of painkillers applied directly to skin, not taken orally, are part of the focus.
May 14, 2026
Haleon PLC Shares Slip as Sensodyne Maker’s £500 Million Buyback Gathers Pace
····

Haleon PLC Shares Slip as Sensodyne Maker’s £500 Million Buyback Gathers Pace

Haleon PLC stock slipped Wednesday after a fresh regulatory filing revealed the Sensodyne owner had snapped up 10,205,329 ordinary shares for cancellation as part of its 2026 buyback program. Those shares were purchased between May 5 and May 8 across the London Stock Exchange, Cboe UK, and Aquis. Once settled, the company will have 8.868 billion ordinary shares with voting rights outstanding. This buyback’s carrying some weight: it’s propping up returns as investors hold out for evidence of faster sales growth. Hargreaves Lansdown’s delayed figures had Haleon off 1.16%, quoted at 331.00p to sell, 331.20p to buy. The FTSE 100, meanwhile, was showing a 0.49% gain.
May 13, 2026
Haleon stock in focus as Google exec hire and £500 million buyback put Sensodyne maker before Q1 test
····

Haleon stock in focus as Google exec hire and £500 million buyback put Sensodyne maker before Q1 test

Haleon PLC on Monday named Richard Manso—who previously held a senior post at Google—as its new U.S. chief marketing officer. The move puts Manso in charge of marketing in Haleon's biggest, highest-profile market, at a time when demand for certain consumer health products is still inconsistent. The timing around the hire is key as Haleon looks to ramp up U.S. growth ahead of its April 29 first-quarter trading update and annual general meeting. Manso steps in to head up the company’s integrated U.S. marketing operations, reporting directly to Nathalie Gerschtein, CEO, U.S. and president, North America, according to Haleon.
April 27, 2026
Haleon PLC Stock Faces Q1 Demand Test After Friday Rebound
····

Haleon PLC Stock Faces Q1 Demand Test After Friday Rebound

Haleon PLC picked up 1.02% to finish Friday at 355.20p in London trading, ahead of what’s expected to be a busy stretch for the consumer-health company. Still, the shares showed a 0.95% drop over the last five sessions and remain 5.23% lower year-to-date, according to MarketScreener data. April 29 is on the radar, with Haleon set to deliver its first trading update since outlining a 3% to 5% organic revenue growth goal for 2026. Organic growth, which excludes impacts from currency shifts and acquisitions, helps investors focus on core sales performance. The company’s 2026 annual meeting lands on the same date, according to its calendar.
April 25, 2026
Haleon PLC Stock Price Today: Q1 Memo Keeps 2026 Growth Questions Alive
····

Haleon PLC Stock Price Today: Q1 Memo Keeps 2026 Growth Questions Alive

Haleon traded flat on Friday, hovering around 366 pence. The company dropped a brief pre-results aide memoire—essentially a heads-up for analysts—ahead of its Q1 trading update set for April 29. It’s important here because Haleon is still working to reassure investors after last month’s call for 2026 organic revenue growth at 3% to 5%, missing the company’s medium-term target of 4% to 6%. Organic revenue figures, which ignore currency moves and recent acquisitions, rattled the market—shares dropped as much as 6% after that February guidance.
March 27, 2026
Haleon PLC Stock Price Rises After Buyback Launch and Berenberg Target Hike
····

Haleon PLC Stock Price Rises After Buyback Launch and Berenberg Target Hike

Haleon climbed on Tuesday, London shares finishing roughly 2.4% higher while the U.S. stock added about 1.5% to $10.62 as of 19:04 UTC. The move followed Berenberg’s target price bump and news that the company had started buying back shares under its fresh £500 million program. This is significant for Haleon, still working to recover after its February 25 forecast for 2026 organic revenue growth landed at 3% to 5%. That’s not just under analysts’ 4.4% consensus estimate—it’s also below the company’s own medium-term target. Organic revenue, importantly, excludes currency moves and the impacts of recent acquisitions or disposals.
March 17, 2026
1 2